BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the BioXL Therapeutics third quarter 2024 earnings conference call. At this time all participants are in listen only mode. If during the conference call you require operator assistance, please press star zero on your telephone keypad. After the formal remarks, there will be a question and answer session. If you'd like to register a question, you may press star one on your telephone keypad. Just to remind everyone, certain matters discussed in today's conference call and or answers that may be given to questions asked or forward-looking statements that are subject to risks and uncertainties related to future events and or the future financial or business performance of the company. Actual results could differ materially from those anticipated in these forward-looking statements. Risk factors that could affect future results are detailed in the company's quarterly report on Form 10-Q for the quarterly period ended June 30th, 2024, which can be found at www.police.gov. bioexceltherapeutics.com or on www.scc.gov, and which will be updated in its quarterly report on Form 10Q for the quarterly period ended September 30, 2024. As a reminder, today's call is being recorded. Speaking on today's call are Dr. Vival Mehta, Chief Executive Officer, and Richard Steinhardt, Chief Financial Officer. We'll be joined in the Q&A session by Dr. Vince O'Neill, Chief of Product Development and Medical Officer, Dr. Frank Yacca, Chief Scientific Officer, and Dr. Rob Reisinger, Chief Medical Officer of Neuroscience. It's now my pleasure to turn the call over to Dr. Mehta. Thank you, operator. Good morning, everyone, and thank you for joining us. This past Tuesday, we announced important milestones with our two pivotal phase C trials with BXL501. These trials are f...